|22nd September 2020||John Kozlowski||87||Payment by withholding||$6.08||$528.96|
|7th September 2020||John Kozlowski||5,000||Grant/award etc.||$0.00|
|7th September 2020||John Abt||10,000||Grant/award etc.||$0.00|
|3rd September 2020||John Abt||1,000||Open or private sale||$5.27||$5,270.00|
|1st September 2020||Melissa Rewolinski||38,986||Grant/award etc.||$0.00|
|1st September 2020||David A Drabik||38,986||Grant/award etc.||$0.00|
|1st September 2020||Paul Taveira||38,986||Grant/award etc.||$0.00|
|1st September 2020||John C Chapman||38,986||Grant/award etc.||$0.00|
|1st September 2020||Jeffrey Farber||38,986||Grant/award etc.||$0.00|
|1st September 2020||Patrick G Lepore||38,986||Grant/award etc.||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 4/10.
Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Philadelphia, PA.